Skip to main content

Advertisement

SpringerLink
Log in

Serum Vascular Endothelial Gowth Factor Correlates with Hasford Score in Chronic Myeloid Leukemia

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Introduction and Aim Increased angiogenesis in BM is one of the characteristics of chronic myeloid leukemia (CML) implicated in its progression. Vascular endothelial growth factor (VEGF) one of the most potent regulator of angiogenesis is increased in CML. The prognostic impact of serum VEGF in CML is largely unknown with sparse literature from India. So the present study aimed to measure serum VEGF levels in different phases of CML and to assess its prognostic significance using Hasford score. Methods Forty Ph + patients of CML were enrolled in the study. Complete clinical history and physical examination was done. Hemogram was done by Beckman Coulter LH 500. Peripheral smear (Wright’s stain) was done by microscopy. Serum VEGF (plain vial) using ELISA was calculated. Statistical analysis was performed using SPSS software version 20. Results The mean serum VEGF levels were significantly higher in patients than in controls (p < 0.0001). The patients in accelerated/blast phase demonstrated significantly higher levels of serum VEGF (mean 151 pg/mL) than those in the chronic phase (mean 90.87 pg/mL) (p = 0.02). Serum VEGF levels showed a significant positive correlation with the overall Hasford prognostic score (p = 0.023). Conclusion Serum VEGF levels can serve as an independent prognostic marker in CML patients irrespective of phase of CML. Also, S. VEGF levels can be used to monitor patients on imatinib therapy and identify those who might benefit from antiangiogenesis therapy. However, larger studies are needed with a larger number of patients in different phases of CML to validate our findings and thus pave the way for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hernández-Boluda JC, Cervantes F (2009) Prognostic factors in chronic myeloid leukaemia. Best Pract Res ClinHaematol 22(3):343–353

    Article  Google Scholar 

  2. Narang NC, Kotru M, Sikka M, Rusia U (2017) Comparison of the applicability of Hasford score and European treatment and outcome study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy. South Asian J Cancer 6(3):117

    Article  Google Scholar 

  3. Sinha SK, Sinha S, Mandal PK, Bhattacharyya NK, Pandey A, Gupta P (2013) A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers. Indian J PatholMicrobiol 56:216–220

    Google Scholar 

  4. Aijaz J, Junaid N, Asif Naveed M, Maab R (2020) Risk stratification of chronic myeloid leukemia according to different prognostic scores. Cureus 12(3):e7342

    PubMed  PubMed Central  Google Scholar 

  5. Zhelyazkova AG, Tonchev AB, Kolova P, Ivanova L, Gercheva L (2008) Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Scand J Clin Lab Invest 68(6):492–500

    Article  CAS  Google Scholar 

  6. Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105(4):1383–1395

    Article  CAS  Google Scholar 

  7. Pandey N, Yadav G, Kushwaha R et al (2019) Effect of imatinib on bone marrow morphology and angiogenesis in chronic myeloid leukemia. AdvHematol. https://doi.org/10.1155/2019/1835091

    Article  Google Scholar 

  8. Chand R, Chandra H, Chandra S, Verma SK (2016) Role of Microvessel density and vascular endothelial growth factor in angiogenesis of hematological malignancies. Bone Marrow Res. https://doi.org/10.1155/2016/5043483

    Article  PubMed  PubMed Central  Google Scholar 

  9. Meena LP, Prakash J, Tandon R, Bharti A, Meena VK, Tripathi K (2013) Study to assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia (CML). Int J Med Sci Public Health 2:48–51

    Article  Google Scholar 

  10. Doig K, Thompson LA (2017) A Methodical Approach to Interpreting the White Blood Cell Parameters of the Complete Blood Count. Clin Lab Sci 30(3):186–193. https://doi.org/10.29074/ascls.30.3.186

    Article  Google Scholar 

  11. Purnomo A, Bintoro UY, Sedana MP, Ashariati A (2019) Association between Hasford Scoring system and hematologic response in chronic and accelerated phase of chronic myelocyticleukemia patient with imatinib for three months. Mol Cell Biomed Sci. 3(2):88–94. https://doi.org/10.21705/mcbs.v3i2.56

    Article  Google Scholar 

  12. Legros L, Bourcier C, Jacquel A, Mahon FX, Cassuto JP, Auberger P et al (2004) Imatinibmesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 104(2):495–501

    Article  CAS  Google Scholar 

  13. Liu P, Li J, Han ZC, Lu H, Wang Y, Xu B et al (2005) Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia. Leuk Lymphoma 46(12):1761–1764

    Article  CAS  Google Scholar 

  14. Almenshaw MS, Ibrahim IA, Khalifa NA, Al-Mursy GZ (2018) Angiogenic activity in chronic myeloid leukemia. J Leuk 6(1):245

    Google Scholar 

  15. Chen H, Shen YF, Gong F, Yang GH, Jiang YQ, Zhang R (2015) Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia. Eur Rev Med PharmacolSci 19(19):3569–3573

    CAS  Google Scholar 

  16. Godoy CR, Levy D, Giampaoli V, Chamone DA, Bydlowski SP, Pereira J (2015) Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis. Braz J Med Biol Res 48:509–514

    Article  CAS  Google Scholar 

  17. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A et al (2002) Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99(6):2265–7

    Article  CAS  Google Scholar 

  18. Krauth MT, Simonitsch I, Aichberger KJ, Mayerhofer M, Sperr WR, Sillaber C et al (2004) Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J ClinPathol 121(4):473–481

    CAS  Google Scholar 

  19. Ghannadan M, Wimazal F, Simonitsch I et al (2003) Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia: correlation between VEGF expression and the FAB category. Am J ClinPathol 119:663–671

    CAS  Google Scholar 

  20. Kaiafa G, Kakaletsis N, Savopoulos C, Perifanis V, Giannouli A, Papadopoulos N et al (2014) Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 39(1):102–105

    Article  CAS  Google Scholar 

Download references

Acknowledgement

We would like to acknowledge Department of Science and Technology, Delhi for their support for this project.

Funding

Yes, Department of Science and Technology, Delhi

Author information

Authors and Affiliations

  1. Department of Pathology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi, 110095, India

    Mrinalini Kotru, Purvi Mathur, Neha Garg, Yogendar Kumar, Meera Sikka & Usha Rusia

Authors
  1. Mrinalini Kotru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Purvi Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neha Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yogendar Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meera Sikka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Usha Rusia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mrinalini Kotru.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical Statement

The study was approved by ethical committee of the institute.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotru, M., Mathur, P., Garg, N. et al. Serum Vascular Endothelial Gowth Factor Correlates with Hasford Score in Chronic Myeloid Leukemia. Indian J Hematol Blood Transfus 38, 61–67 (2022). https://doi.org/10.1007/s12288-021-01437-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-021-01437-6

Keywords

Search

Navigation